Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 243 for “"SCLC"”.
-
Διαλυτά επίπεδα TNF-a σε ασθενείς με SCLC
ΣΚΟΠΟΣ Μελέτη της μεταβολής των επιπέδων του TNF-a στον ορό αίματος ασθενών με ΜΚΠ και συσχέτιση με την ανταπόκριση στη θεραπεία (προβλεπτικός παράγοντας) και ανάλογα συσχέτιση των επιπέδων των ασθενών κατά τη διάγνωση με τα αντίστοιχα των μαρτύρων (διαγνωστικός δείκτης). ΜΕΘΟΔΟΣ Συμμετείχαν …
-
Η προγνωστική σημασία των επιπέδων προκαλσιτονίνης σε ασθενείς με SCLC
… Ο μικροκυτταρικός καρκίνος του πνεύμονα (SCLC), ανήκει στα νευροενδοκρινή καρκινώματα και απαριθμεί περίπου το 15% των καρκίνων του πνεύμονα. Εξελίσσεται ταχύτατα και δίνει γρήγορα μεταστάσεις. Μέχρι σήμερα παραμένει επιτακτική η ανάγκη ανεύρεσης προγνωστικών βιοδεικτών για τη …
-
Succeeding King: Ralph David Abernathy, SCLC, And The Long Civil Rights Movement
… and the Voting Rights Act of 1965, King and his SCLC colleagues shifted the focus of their work to improving economic opportunities for America’s poor citizens. To combat poverty, King planned an ambitious protest designed to force Lyndon Johnson and the U.S. Congress to face the stark reality …
-
Η προγνωστική αξία της πλευριτικής συλλογής στο μικροκυτταρικό καρκίνο του πνεύμονα (SCLC).
… συλλογής στο μικροκυτταρικό καρκίνο πνεύμονα (SCLC). Εισαγωγή Ο μικροκυτταρικός καρκίνος πνεύμονα (small cell lung cancer, SCLC) αποτελεί περίπου το 15% των περιπτώσεων καρκίνου του πνεύμονα. Η πρόγνωση των ασθενών με SCLC παραμένει δυσμενής. Ο σημαντικότερος προγνωστικός δείκτης είναι το …
-
Επίπεδα ορού λεπτίνης και κυτταροκινών (κυτοκινών) σε ασθενείς με μικροκυτταρικό καρκίνο του πνεύμονα (SCLC), συσχέτιση με κλινικές και παθολογοανατομικές παραμέτρους
… tissue in generalized inflammatory state of SCLC patients and the possible use of leptin, adiponectin, resistin, and ghrelin as diagnostic and prognostic markers. Supplementary, we have also examined the behavior of proinflammatory cytokines IL-6 and TNF-a. Correlation of adipose tissue with …
-
Inhibition of Karyopherin-β1-Mediated Nuclear Import of Lineage-Defining Transcription Factors in Small Cell Lung Cancer
Small cell lung cancer (SCLC) is an aggressive neuroendocrine tumor that accounts for approximately 16% of lung cancer diagnoses. Recent genomic studies support the classification of this disease into four different subtypes based on the expression of the lineage-defining transcription factors …
-
Using Genome-Wide CRISPR/Cas9 Screens to Identify Novel Therapeutic Targets in Small Cell Lung Cancer
Small Cell Lung Cancer (SCLC) is a highly aggressive and metastatic form of lung cancer and is one of the most lethal sold tumor malignancies. The classical subtype of SCLC is noted for its neuroendocrine differentiation features. Standard treatment options have not improved in decades and SCLC …
-
Histone Lysine Demethylase KDM4A as a Therapeutic Target for Small Cell Lung Cancer
Small cell lung cancer (SCLC) arises from neuroendocrine cells within the lung. Along with deletion or loss-of-function RB1 and TP53 mutations, which occur in almost all cases, subsets of SCLC are driven by specific lineage transcription factors including ASCL1, NEUROD1, POU2F3, or YAP1. The …
-
Identifying the Origins of Heterogeneity and Plasticity in Small Cell Lung Cancer and Other Neuroendocrine Tumors
<p>Small cell lung cancer (SCLC) and olfactory neuroblastoma (ONB) are aggressive malignancies with neuroendocrine (NE) features, poor outcomes, and limited therapeutic options. Despite being clinically treated as a uniform entity, SCLC exhibits remarkable molecular and phenotypic heterogeneity, …
-
Investigating Drivers of Chemoresistance in Small Cell Lung Cancer
Small cell lung cancer (SCLC) is an aggressive neuroendocrine cancer characterized by initial chemosensitivity followed by rapid emergence of chemoresistant disease. To study the role of MYC family members in SCLC chemoresistance we utilized genetically engineered mouse models of SCLC and found …
-
Modulation of Immune Cell Responses by Small Cell Lung Cancer Cells
Small Cell Lung Cancer (SCLC) accounts for 15-20% of all lung cancers and<br/>kills at least one person every 2 hours in the UK. There is no effective<br/>treatment and overall 2-year survival is less than 5%. Patients with SCLC have<br/>poorly understood local and systemic immune defects. Previous …
-
In vivo functional screens reveal KEAP1 loss as a driver of chemoresistance in small cell lung cancer
… of all cancer types, small cell lung cancer (SCLC) exhibits dismal clinical outcomes owing to rapid transition to chemoresistance. Elucidating the genetic underpinnings of chemoresistance has been challenging owing to limitations with cellular models. Patient derived xenograft (PDX) models …
-
Tumour microenvironment interactions of small cell lung cancer
Small cell lung cancer (SCLC) is characterised by rapid growth, early metastatic spread and poor long-term survival. The tumour is initially sensitive to chemotherapy and thus objective response rates are high. Unfortunately, this response is often short-lived and SCLC recurs with acquired drug …
-
The role of specific genomic alterations in small cell lung cancer aggressiveness
Small Cell Lung Cancer (SCLC) is a very aggressive neuroendocrine tumour of the lung, which demonstrates a 5 year survival of only 10% for extensive stage disease (20-30% for limited stage), with only modest improvement over the last few decades. Identification of new molecular diagnostic and …
-
Das großzellig-neuroendokrine Lungenkarzinom - eine vergleichende Untersuchung zu demographischen und klinischen Eigenschaften, zur Therapie und Prognose
… nicht vor. Daher wird das LCNEC vielfach wie ein SCLC behandelt. In der vorliegenden Arbeit wurde retrospektiv untersucht, inwieweit sich klinische und demographische Eigenschaften sowie Therapieansprechen und Prognose des LCENC und des SCLC unterscheiden. Es sollte die Frage erörtert werden, ob …
-
A new oncogenic function of the glycolytic enzyme lactate dehydrogenase-A in small cell lung cancer
Small Cell Lung Cancer (SCLC) is an epithelial cancer that has, until recent years, been labeled a recalcitrant tumor type. Since its discovery and classification, there has been very little research to understand and treat SCLC. Conventional methods of treatment for SCLC include chemotherapeutics …
-
Hypoxic Adaptation and Arsenic Trioxide Treatment in Small Cell Lung Carcinoma
Small cell lung carcinoma (SCLC) is a very aggressive solid tumor and is often widely metastasized by the time of diagnosis. Despite good response to the initial chemotherapy, SCLC cells often develop multidrug resistance to conventionally used chemotherapeutic drugs, which cause almost all SCLC …
-
UNDERSTANDING AND TARGETING THE TPH1-SEROTONIN-HTR3A AXIS IN SMALL CELL LUNG CANCER
Small cell lung cancer (SCLC), which accounts for 10-15% of all lung cancer, is the most malignant type that tends to grow fast and spread in its early stages. The 5-year survival rate remains low at 6% overall. Thus, new therapeutic methods and pharmacological targets for SCLC patients are …
-
Small cell lung cancer and cancer stem cell-like cells
Small cell lung cancer (SCLC) is a highly aggressive malignancy with extreme mortality and morbidity. Although initially chemo- and radio-sensitive, almost inevitable recurrence and resistance occurs. SCLC patients often present with metastases, making surgery not feasible. Current therapies, …
Page 1 of 13